STF-31536

STF-31536 is a small molecule inhibitor of glucose transport, specifically targeting the glucose transporter 1 (GLUT1). It was identified through a synthetic lethal screen for compounds selectively cytotoxic to von Hippel-Lindau (VHL)-deficient renal cell carcinoma (RCC) cells. VHL-deficient cells often exhibit elevated expression of GLUT1 and VEGF due to the stabilization of hypoxia-inducible factors (HIF). STF-31536 binds directly to GLUT1, disrupting glucose uptake and inducing cell death in a HIF-dependent manner. Research indicates its potential for treating VHL-deficient cancers both in vitro and in vivo.